ID   Y-79
AC   CVCL_1893
SY   Y79; GM01232; GM01232E
DR   BTO; BTO:0002920
DR   CLO; CLO_0009709
DR   CLO; CLO_0030277
DR   CLO; CLO_0051564
DR   EFO; EFO_0002392
DR   CLDB; cl4796
DR   CLDB; cl4798
DR   CLDB; cl4797
DR   CLDB; cl4984
DR   AddexBio; C0029001/4898
DR   ArrayExpress; E-MTAB-38
DR   BCRC; 60422
DR   BCRJ; 0380
DR   BioSample; SAMN00803744
DR   BioSample; SAMN01821607
DR   BioSample; SAMN03472733
DR   BioSample; SAMN03473388
DR   cancercelllines; CVCL_1893
DR   Cell_Model_Passport; SIDM01395
DR   ChEMBL-Cells; CHEMBL3308054
DR   ChEMBL-Targets; CHEMBL613820
DR   CLS; 300382
DR   Coriell; GM01232
DR   Cosmic; 688120
DR   Cosmic; 808507
DR   Cosmic; 1071899
DR   Cosmic; 1176623
DR   DepMap; ACH-001295
DR   DSMZ; ACC-246
DR   DSMZCellDive; ACC-246
DR   ECACC; 86093003
DR   GEO; GSM1250686
DR   GEO; GSM1250688
DR   GEO; GSM1486288
DR   GEO; GSM2043882
DR   IBRC; C11182
DR   ICLC; HTL99029
DR   IGRhCellID; Y79
DR   NCBI_Iran; C201
DR   Progenetix; CVCL_1893
DR   PubChem_Cell_line; CVCL_1893
DR   RCB; RCB0427
DR   RCB; RCB1645
DR   Wikidata; Q54995129
RX   CelloPub=CLPUB00447;
RX   DOI=10.3969/j.issn.1673-713X.2017.04.002;
RX   DOI=10.5005/jp-journals-10082-02230;
RX   DOI=10.5795/jjscc.24.451;
RX   PubMed=679190;
RX   PubMed=1679230;
RX   PubMed=2917337;
RX   PubMed=3413073;
RX   PubMed=3518877;
RX   PubMed=4135597;
RX   PubMed=6167750;
RX   PubMed=6351622;
RX   PubMed=7499444;
RX   PubMed=7689221;
RX   PubMed=18036396;
RX   PubMed=18799932;
RX   PubMed=19686387;
RX   PubMed=20215515;
RX   PubMed=21697133;
RX   PubMed=23498719;
RX   PubMed=25326674;
RX   PubMed=27050416;
RX   PubMed=27115612;
RX   PubMed=29162051;
RX   PubMed=29192327;
RX   PubMed=30584916;
RX   PubMed=32123578;
RX   PubMed=32143590;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Doubling time: 52 hours (PubMed=4135597); 47 hours (PubMed=25326674); 24-28 hours (DOI=10.5005/jp-journals-10082-02230); ~40 hours (DSMZ=ACC-246).
CC   HLA typing: A*02:01:01; B*40:01:02,51:01:01; C*03:04:01,12:03:01; DPB1*03:01,04:01; DQA1*01:01:01,01:02:01; DQB1*05:01:01,06:04:01; DRB1*01:01:01,13:02:01 (CLS=300382).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; Ex2-6del; Zygosity=Heterozygous (PubMed=3413073; PubMed=25326674).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; IVS20+1G>A; Zygosity=Heterozygous (PubMed=3413073; PubMed=25326674).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Anecdotal: Named Y-79 because it was the result of the 79th attempt of a group at Yale to establish a retinoblastoma cell line.
CC   Discontinued: JCRB; KURB2684; probable.
CC   Discontinued: RCB; RCB0427; true.
CC   Derived from site: In situ; Eye, globe; UBERON=UBERON_0010230.
ST   Source(s): AddexBio=C0029001/4898; ATCC=HTB-18; CLS=300382; DepMap=ACH-001295; DSMZ=ACC-246; ECACC=86093003; ICLC=HTL99029; JCRB=JCRB3020; RCB=RCB1645
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D16S539: 13,14
ST   D18S51: 13,16
ST   D19S433: 13
ST   D21S11: 30,32
ST   D2S1338: 20
ST   D3S1358: 15,16
ST   D5S818: 11 (ICLC=HTL99029)
ST   D5S818: 11,12 (AddexBio=C0029001/4898; ATCC=HTB-18; CLS=300382; DepMap=ACH-001295; DSMZ=ACC-246; ECACC=86093003; JCRB=JCRB3020; RCB=RCB1645)
ST   D7S820: 8,9
ST   D8S1179: 13,16
ST   FGA: 20,22 (ATCC=HTB-18; DepMap=ACH-001295; DSMZ=ACC-246)
ST   FGA: 22 (CLS=300382)
ST   Penta D: 12
ST   Penta E: 13,18
ST   TH01: 6 (JCRB=JCRB3020)
ST   TH01: 6,9.3 (AddexBio=C0029001/4898; ATCC=HTB-18; CLS=300382; DepMap=ACH-001295; ECACC=86093003; ICLC=HTL99029; RCB=RCB1645)
ST   TH01: 6,10 (DSMZ=ACC-246)
ST   TPOX: 8
ST   vWA: 15,18
DI   NCIt; C7541; Retinoblastoma
DI   ORDO; Orphanet_790; Retinoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   2Y6M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 39
RX   CelloPub=CLPUB00447;
RA   Mulivor R.A., Suchy S.F.;
RT   "1992/1993 catalog of cell lines. NIGMS human genetic mutant cell
RT   repository. 16th edition. October 1992.";
RL   (In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992).
RX   DOI=10.3969/j.issn.1673-713X.2017.04.002;
RA   Song W.-P., Zhang C.-Y., Zhang Y., Li Y., Cao R., Ye C., Zhang L.,
RA   Shao R.-G., Li L., Zhao J.-Y.;
RT   "Generation of etoposide-resistant subline of human retinoblastoma Y79
RT   cells and preliminary study of its resistance mechanism.";
RL   Zhongguo Yiyao Sheng Wu Jishu 12:297-302(2017).
RX   DOI=10.5005/jp-journals-10082-02230;
RA   Kuduvalli S.S., Ramalakshmi O., Precilla S.D., Anitha T.S.;
RT   "Evaluation of cell doubling time in C6 and Y79 cell lines based on
RT   seeding density.";
RL   SBV J. Basic Clin. Appl. Heatlh Sci. 2:146-149(2019).
RX   DOI=10.5795/jjscc.24.451;
RA   Tsumuraya M., Nakajima T., Terasaki T., Kodama T., Shimosato Y.,
RA   Higuchi H., Uei Y.;
RT   "Analysis of LDH isoenzyme patterns in cell lines of the small cell
RT   carcinoma (lung) and retinoblastoma.";
RL   Nihon Rinsho Saibo Gakkai Zasshi 24:451-456(1985).
RX   PubMed=679190;
RA   McFall R.C., Nagy R.M., Nagle B.T., McGreevy L.M.;
RT   "Scanning electron microscopic observation of two retinoblastoma cell
RT   lines.";
RL   Cancer Res. 38:2827-2835(1978).
RX   PubMed=1679230; DOI=10.3109/13816819109023085;
RA   Madreperla S.A., Bookstein R., Jones O.W., Lee W.-H.;
RT   "Retinoblastoma cell lines Y79, RB355 and WERI-Rb27 are genetically
RT   related.";
RL   Ophthalmic Paediatr. Genet. 12:49-56(1991).
RX   PubMed=2917337; DOI=10.1016/0165-4608(89)90079-4;
RA   Horsthemke B., Greger V., Becher R., Passarge E.;
RT   "Mechanism of i(6p) formation in retinoblastoma tumor cells.";
RL   Cancer Genet. Cytogenet. 37:95-102(1989).
RX   PubMed=3413073; DOI=10.1073/pnas.85.16.6017;
RA   Lee E.Y.-H.P., Bookstein R., Young L.-J., Lin C.-J., Rosenfeld M.G.,
RA   Lee W.-H.;
RT   "Molecular mechanism of retinoblastoma gene inactivation in
RT   retinoblastoma cell line Y79.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:6017-6021(1988).
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
RX   PubMed=4135597; DOI=10.1093/jnci/53.2.347;
RA   Reid T.W., Albert D.M., Rabson A.S., Russell P., Craft J.L., Chu E.W.,
RA   Tralka T.S., Wilcox J.L.;
RT   "Characteristics of an established cell line of retinoblastoma.";
RL   J. Natl. Cancer Inst. 53:347-360(1974).
RX   PubMed=6167750; DOI=10.1093/jnci/67.2.301;
RA   Gilbert F., Balaban G.B., Breg W.R., Gallie B.L., Reid T.W.,
RA   Nichols W.W.;
RT   "Homogeneously staining region in a retinoblastoma cell line:
RT   relevance to tumor initiation and progression.";
RL   J. Natl. Cancer Inst. 67:301-306(1981).
RX   PubMed=6351622; DOI=10.1016/S0002-9394(14)77822-5;
RA   Ohashi Y., Sasabe T., Nishida T., Nishi Y., Higashi H.;
RT   "Hanganutziu-Deicher heterophile antigen in human retinoblastoma
RT   cells.";
RL   Am. J. Ophthalmol. 96:321-325(1983).
RX   PubMed=7499444; DOI=10.1007/BF01213319;
RA   Inomata M., Saijo N., Kawashima K., Kaneko A., Fujiwara Y.,
RA   Kunikane H., Tanaka Y.;
RT   "Induction of apoptosis in cultured retinoblastoma cells by the
RT   protein phosphatase inhibitor, okadaic acid.";
RL   J. Cancer Res. Clin. Oncol. 121:729-738(1995).
RX   PubMed=7689221; DOI=10.1073/pnas.90.16.7578;
RA   Godbout R., Squire J.A.;
RT   "Amplification of a DEAD box protein gene in retinoblastoma cell
RT   lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:7578-7582(1993).
RX   PubMed=18036396; DOI=10.1016/j.cancergencyto.2007.08.014;
RA   Paderova J., Orlic-Milacic M., Yoshimoto M., da Cunha Santos G.,
RA   Gallie B.L., Squire J.A.;
RT   "Novel 6p rearrangements and recurrent translocation breakpoints in
RT   retinoblastoma cell lines identified by spectral karyotyping and mBAND
RT   analyses.";
RL   Cancer Genet. Cytogenet. 179:102-111(2007).
RX   PubMed=18799932; DOI=10.1097/MPH.0b013e31816e232d;
RA   Kim J.H., Kim J.H., Yu Y.S., Kim D.H., Kim Y.K., Kim K.-W.;
RT   "Comparative genomic hybridization analysis of newly established
RT   retinoblastoma cell lines of adherent growth compared with Y79 of
RT   nonadherent growth.";
RL   J. Pediatr. Hematol. Oncol. 30:571-574(2008).
RX   PubMed=19686387; DOI=10.1111/j.1471-4159.2009.06322.x;
RA   Glubrecht D.D., Kim J.-H., Russell L., Bamforth J.S., Godbout R.;
RT   "Differential CRX and OTX2 expression in human retina and
RT   retinoblastoma.";
RL   J. Neurochem. 111:250-263(2009).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=21697133; DOI=10.1167/iovs.11-7479;
RA   Oshikawa M., Tsutsui C., Ikegami T., Fuchida Y., Matsubara M.,
RA   Toyama S., Usami R., Ohtoko K., Kato S.;
RT   "Full-length transcriptome analysis of human retina-derived cell lines
RT   ARPE-19 and Y79 using the vector-capping method.";
RL   Invest. Ophthalmol. Vis. Sci. 52:6662-6670(2011).
RX   PubMed=23498719; DOI=10.1016/S1470-2045(13)70045-7;
RA   Rushlow D.E., Mol B.M., Kennett J.Y., Yee S., Pajovic S.,
RA   Theriault B.L., Prigoda-Lee N.L., Spencer C., Dimaras H., Corson T.W.,
RA   Pang R., Massey C., Godbout R., Jiang Z., Zacksenhaus E., Paton K.,
RA   Moll A.C., Houdayer C., Raizis A., Halliday W., Lam W.L.,
RA   Boutros P.C., Lohmann D.R., Dorsman J.C., Gallie B.L.;
RT   "Characterisation of retinoblastomas without RB1 mutations: genomic,
RT   gene expression, and clinical studies.";
RL   Lancet Oncol. 14:327-334(2013).
RX   PubMed=25326674; DOI=10.1007/s00418-014-1285-z;
RA   Busch M.A., Philippeit C., Weise A., Dunker N.;
RT   "Re-characterization of established human retinoblastoma cell lines.";
RL   Histochem. Cell Biol. 143:325-338(2015).
RX   PubMed=27050416; DOI=10.1371/journal.pone.0153011;
RA   Ferrario A., Luna M., Rucker N., Wong S., Lederman A., Kim J.,
RA   Gomer C.;
RT   "Targeting survivin enhances chemosensitivity in retinoblastoma cells
RT   and orthotopic tumors.";
RL   PLoS ONE 11:E0153011-E0153011(2016).
RX   PubMed=27115612; DOI=10.1371/journal.pone.0153323;
RA   Kooi I.E., Mol B.M., Massink M.P.G., de Jong M.C., de Graaf P.,
RA   van der Valk P., Meijers-Heijboer H., Kaspers G.J.L., Moll A.C.,
RA   te Riele H., Cloos J., Dorsman J.C.;
RT   "A meta-analysis of retinoblastoma copy numbers refines the list of
RT   possible driver genes involved in tumor progression.";
RL   PLoS ONE 11:E0153323-E0153323(2016).
RX   PubMed=29162051; DOI=10.1186/s12885-017-3750-2;
RA   Nair R.M., Balla M.M.S., Khan I., Kalathur R.K.R., Kondaiah P.,
RA   Vemuganti G.K.;
RT   "In vitro characterization of CD133(lo) cancer stem cells in
RT   retinoblastoma Y79 cell line.";
RL   BMC Cancer 17:779.1-779.12(2017).
RX   PubMed=29192327; DOI=10.3892/or.2017.6100;
RA   Busch M.A., Papior D., Stephan H., Dunker N.;
RT   "Characterization of etoposide- and cisplatin-chemoresistant
RT   retinoblastoma cell lines.";
RL   Oncol. Rep. 39:160-172(2018).
RX   PubMed=30584916; DOI=10.1016/j.yexcr.2018.12.018;
RA   Schwermer M., Hiber M., Dreesmann S., Rieb A., Theissen J., Herold T.,
RA   Schramm A., Temming P., Steenpass L.;
RT   "Comprehensive characterization of RB1 mutant and MYCN amplified
RT   retinoblastoma cell lines.";
RL   Exp. Cell Res. 375:92-99(2019).
RX   PubMed=32123578; DOI=10.1038/s41420-020-0237-8;
RA   Aubry A., Yu T., Bremner R.;
RT   "Preclinical studies reveal MLN4924 is a promising new retinoblastoma
RT   therapy.";
RL   Cell Death Discov. 6:2.1-2.12(2020).
RX   PubMed=32143590; DOI=10.1186/s12886-020-01348-6;
RA   Song W.-P., Zheng S., Yao H.-J., Zhou X.-F., Li R., Zhang C.-Y.,
RA   Zhao J.-Y., Wang L.-W., Shao R.-G., Li L.;
RT   "Different transcriptome profiles between human retinoblastoma Y79
RT   cells and an etoposide-resistant subline reveal a chemoresistance
RT   mechanism.";
RL   BMC Ophthalmol. 20:92.1-92.11(2020).